GSE208721
Chemo-immonotherapeutic effects of  PD-L1-targeted antibody-catalyst conjugate plus DOX prodrug in a mouse model of colon cancer
We designed a study to investiagate chemo-immunotheraputic effect using a mouse model of colon cancer. To investigate the anti-tumor effect of the combination therapy, the in vivo antitumor activities of different mono- and combinational therapy were subsequently evaluated using a C57BL/6J mouse model bearing MC38 tumors. Subcutaneous injection of 1×106 of MC38 cells in the right flank of a mouse was performed 9 days before therapy. The Ru-PD-L1 was administrated by intraperitoneal injection, while the DPD or DOX was given by peritumoral injection. For combinational treatment, each mouse was treated with 14 µg DPD or DOX (0.56 mg/kg) 6 hours after administering 20 ug Ru-PD-L1 (0.80mg/kg). For monotherapy, each mouse was treated with Ru-PD-L1, DPD, or DOX alone.  On the 20th day, the mice were sacrificed for tumor collection. The results highlighted that the combination of ACC and DOX prodrug synergistically enhanced immune response and higher antitumor activity compared to the ACC and DOX combination. Overall design: Comparative gene expression profiling analysis of RNA-seq data for (1) Control; (2) DOX; (3) DPD; (4) Ru-PD-L1; (5) Ru-PD-L1+DOX; (6) Ru-PD-L1+DPD treated tumor bearing mice.